Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.

Wattjes MP, Barkhof F.

Curr Opin Neurol. 2014 Jun;27(3):260-70. doi: 10.1097/WCO.0000000000000099. Review.

PMID:
24739400
2.

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.

Mult Scler. 2013 Dec;19(14):1826-40. doi: 10.1177/1352458513510224. Epub 2013 Nov 5. Review.

PMID:
24192217
3.

MRI pattern in asymptomatic natalizumab-associated PML.

Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AE, Frequin ST, Richert ND, Barkhof F.

J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):793-8. doi: 10.1136/jnnp-2014-308630. Epub 2014 Sep 9.

PMID:
25205744
4.

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

Wattjes MP, Vennegoor A, Mostert J, van Oosten BW, Barkhof F, Killestein J.

J Neurol. 2014 Jun;261(6):1139-43. doi: 10.1007/s00415-014-7336-5. Epub 2014 Apr 6.

PMID:
24705790
5.

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M.

Ann Neurol. 2012 Nov;72(5):779-87. doi: 10.1002/ana.23676.

PMID:
23280794
6.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
7.

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.

Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W.

Acta Neuropathol. 2012 Feb;123(2):235-45. doi: 10.1007/s00401-011-0900-5. Epub 2011 Nov 6.

8.

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.

JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. Review.

PMID:
23338729
9.

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.

Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1068-74. doi: 10.1136/jnnp-2013-304897. Epub 2013 Apr 19.

10.

Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical?

Arnaud FX, Hissene A, Métivier D, Dutasta F, Berets O, N'guema B, A'teriitéhau C, Baccialone J, Potet J.

J Neuroradiol. 2012 Oct;39(4):267-70. doi: 10.1016/j.neurad.2011.12.005. Epub 2012 Feb 16.

11.

Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.

Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.

J Neuroimaging. 2014 Jul-Aug;24(4):425-8. doi: 10.1111/jon.12010. Epub 2013 Jan 16.

PMID:
23323645
12.

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.

Baldwin KJ, Hogg JP.

Curr Opin Neurol. 2013 Jun;26(3):318-23. doi: 10.1097/WCO.0b013e328360279f. Review.

PMID:
23493158
13.

[[Natalizumab therapy, 2013].

Karácsony M, Bencsik K, Vécsei L.

Ideggyogy Sz. 2014 Jul 30;67(7-8):220-8. Review. Hungarian.

PMID:
25509362
14.

Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?

Cutter GR, Stüve O.

Mult Scler. 2014 Sep;20(10):1304-5. doi: 10.1177/1352458514531843. Epub 2014 May 8.

PMID:
24812045
15.

Immunological and clinical consequences of treating a patient with natalizumab.

Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner MP, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Brück W, Wiendl H.

Mult Scler. 2012 Mar;18(3):335-44. doi: 10.1177/1352458511421919. Epub 2011 Sep 9.

PMID:
21908480
16.

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

Phan-Ba R, Lommers E, Tshibanda L, Calay P, Dubois B, Moonen G, Clifford D, Belachew S.

J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):224-6. doi: 10.1136/jnnp-2011-300511. Epub 2011 Oct 19.

PMID:
22013244
17.

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.

Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.

J Neuropathol Exp Neurol. 2012 Jul;71(7):604-17. doi: 10.1097/NEN.0b013e31825caf2c. Review.

PMID:
22710964
18.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Aksamit AJ.

Neurologist. 2006 Nov;12(6):293-8. Review.

PMID:
17122725
19.

Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.

Landy DC, Hecht EM.

Clin Neuropharmacol. 2014 Mar-Apr;37(2):45-51. doi: 10.1097/WNF.0000000000000018.

PMID:
24614671
20.

Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.

Carruthers RL, Chitnis T, Healy BC.

Mult Scler. 2014 May;20(6):757-60. doi: 10.1177/1352458513509509. Epub 2013 Nov 4.

PMID:
24189572

Supplemental Content

Support Center